Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1400397rdf:typepubmed:Citationlld:pubmed
pubmed-article:1400397lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:1400397lifeskim:mentionsumls-concept:C0036751lld:lifeskim
pubmed-article:1400397lifeskim:mentionsumls-concept:C0521390lld:lifeskim
pubmed-article:1400397lifeskim:mentionsumls-concept:C0002667lld:lifeskim
pubmed-article:1400397lifeskim:mentionsumls-concept:C0038734lld:lifeskim
pubmed-article:1400397lifeskim:mentionsumls-concept:C0162758lld:lifeskim
pubmed-article:1400397lifeskim:mentionsumls-concept:C0596902lld:lifeskim
pubmed-article:1400397lifeskim:mentionsumls-concept:C0687133lld:lifeskim
pubmed-article:1400397lifeskim:mentionsumls-concept:C1705241lld:lifeskim
pubmed-article:1400397lifeskim:mentionsumls-concept:C0205224lld:lifeskim
pubmed-article:1400397lifeskim:mentionsumls-concept:C1705242lld:lifeskim
pubmed-article:1400397pubmed:issue29lld:pubmed
pubmed-article:1400397pubmed:dateCreated1992-11-18lld:pubmed
pubmed-article:1400397pubmed:abstractTextThe sulfhydryl-selective alkylating agent, N-ethylmaleimide (NEM), has been used as a tool to discern whether different binding domains exist on the neuronal serotonin (5-HT) transporter for 5-HT and 5-HT uptake inhibitors (Reith, M. E. A., Allen, D. L., Sershen, H., and Lajtha, A. (1984) J. Neurochem. 43, 249-255; Graham, D., Esnaud, H., Habert, E., and Langer, S. Z. (1989) Biochem. Pharmacol. 38, 3819-3826). However, relatively high concentrations of NEM and long incubation times have been required for inactivation of the transporter-binding site which raises the possibility that NEM is reacting with other nucleophilic groups (Smyth, D. G., Blumenfeld, O. O., and Konigsberg, W. (1964) Biochem. J. 91, 589-595). In the present work, the reactivity and essential nature of sulfhydryl groups associated with substrate/inhibitor binding to the neuronal 5-HT transporter was assessed. [3H]Paroxetine, a potent and selective 5-HT uptake inhibitor, was used to label the 5-HT transporter. The effects of a relatively wide range of sulfhydryl reagents on [3H]paroxetine binding in digitoninsolubilized preparations of rat brain neuronal membranes and the relative abilities of different classes of drugs to protect against NEM-induced inactivation of [3H]paroxetine binding were studied. It was observed that digitonin-solubilized preparations were more sensitive than membrane preparations to the inactivating effects of NEM. The pKa of the reactive group was estimated to be 6.17, in the range expected for a reactive sulfhydryl. Sulfhydryls essential to ligand binding reacted preferentially with hydrophobic compounds (p-hydroxymercuribenzoate = dithiobisnitrobenzoate > methyl methanethiosulfonate > N-phenylmaleimide > N-ethylmaleimide) and were unreactive toward hydrophilic reagents such as iodoacetate and iodoacetamide. 5-HT, 5-HT uptake inhibitors and cocaine protected the digitonin-solubilized transporter from NEM-induced inactivation while the amphetamine-related releasing agents p-chloroamphetamine and fenfluramine were ineffective. The observation that the binding of some, but not all, ligands requires reduced sulfhydryl groups, suggests that differential mechanisms and/or different binding domains do exist for agents which interact at the neuronal 5-HT transporter.lld:pubmed
pubmed-article:1400397pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:languageenglld:pubmed
pubmed-article:1400397pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:citationSubsetIMlld:pubmed
pubmed-article:1400397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1400397pubmed:statusMEDLINElld:pubmed
pubmed-article:1400397pubmed:monthOctlld:pubmed
pubmed-article:1400397pubmed:issn0021-9258lld:pubmed
pubmed-article:1400397pubmed:authorpubmed-author:KuhnD MDMlld:pubmed
pubmed-article:1400397pubmed:authorpubmed-author:WolfW AWAlld:pubmed
pubmed-article:1400397pubmed:issnTypePrintlld:pubmed
pubmed-article:1400397pubmed:day15lld:pubmed
pubmed-article:1400397pubmed:volume267lld:pubmed
pubmed-article:1400397pubmed:ownerNLMlld:pubmed
pubmed-article:1400397pubmed:authorsCompleteYlld:pubmed
pubmed-article:1400397pubmed:pagination20820-5lld:pubmed
pubmed-article:1400397pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:meshHeadingpubmed-meshheading:1400397-...lld:pubmed
pubmed-article:1400397pubmed:year1992lld:pubmed
pubmed-article:1400397pubmed:articleTitleRole of essential sulfhydryl groups in drug interactions at the neuronal 5-HT transporter. Differences between amphetamines and 5-HT uptake inhibitors.lld:pubmed
pubmed-article:1400397pubmed:affiliationLafayette Clinic, Detroit, Michigan 48207.lld:pubmed
pubmed-article:1400397pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1400397pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed